4DMT Reports Q1 Revenue of $3.05M, Beating Consensus
Reports Q1 revenue $3.05M, consensus $2.59M. "We started 2026 with strong execution, completing enrollment in 4FRONT-1 ahead of schedule reflecting strong investigator and patient enthusiasm for 4D-150," said David Kirn, Co-founder, President and Chief Executive Officer of 4DMT. "For the remainder of the year, we look forward to completing 4FRONT-2 enrollment, initiating our global Phase 3 clinical trial in DME, and sharing 2-year data from PRISM and SPECTRA."
